1. Phylogeny  
   Cyclin‐dependent kinase 18 (CDK18), also known as PCTAIRE3 or PCTK3, is phylogenetically classified as an atypical member within the broader cyclin‐dependent kinase family. Unlike classical cell cycle regulators such as CDK1, CDK2, CDK4, and CDK6, CDK18 is part of the PCTAIRE subfamily that diverged evolutionarily through the replacement of the canonical PSTAIRE helix with a PCTAIRE motif. This unique substitution is present in the central catalytic domain and is known to modulate its cyclin association and regulatory properties (alonso2021caracterizacióndecdk1418 pages 114-118). The PCTAIRE subfamily, which also comprises CDK16 (PCTAIRE1) and CDK17 (PCTAIRE2), is thought to have evolved from an ancestral CDK5-related gene, leading to a specialized group of kinases expressed predominantly in terminally differentiated cells rather than in rapidly dividing cells. Phylogenetic analyses have demonstrated that these kinases share considerable sequence similarity, particularly within their catalytic domains; however, they have acquired differences in regulatory regions that are believed to be instrumental in conferring non-cell cycle–related functions (alonso2021caracterizacióndecdk1418 pages 29-32). Although classical CDKs are ubiquitously conserved across eukaryotes, members of the PCTAIRE subgroup, including CDK18, emerged later in the evolution of metazoans. Their orthologs have been identified in multiple mammalian species, and expression profiling indicates a tissue‐restricted pattern that frequently corresponds to cells with terminal differentiation, such as neurons, germ cells, and cells in the gastrointestinal tract (pepino2021overviewofpctk3cdk18 pages 1-2, malumbres2014cyclindependentkinases pages 3-5). This phylogenetic context underscores the notion that CDK18 and its related PCTAIRE kinases represent an evolutionarily derived subset of CDKs that have adapted to fulfill specialized roles in signal transduction and cellular homeostasis, rather than directly driving the proliferative cycle (karimbayli2024insightsintothe pages 1-2).
2. Reaction Catalyzed  
   CDK18 catalyzes the ATP-dependent phosphorylation of serine and threonine residues on substrate proteins, a reaction that is central to its function as a signal transduction modulator in terminally differentiated cells. The chemical reaction involves the binding of ATP in the active site; coordinated by divalent metal ions, typically Mg²⁺, the kinase transfers the terminal γ-phosphate group of ATP to specific hydroxyl groups present on serine or threonine residues of the substrate proteins (alonso2021caracterizacióndecdk1418 pages 35-38). In biochemical terms, the reaction can be summarized as follows: ATP + [protein]–(L‑serine or L‑threonine) → ADP + [protein]–(L‑serine/threonine)-phosphate + H⁺, consistent with the phosphoryl transfer mechanism that is a hallmark of serine/threonine kinases (chowdhury2023cmgckinasesin pages 2-4). Although comprehensive data regarding the exact in vivo substrates remain limited, early studies suggest that CDK18 exhibits a substrate preference that may include components of vesicle trafficking, cytoskeletal regulators, and elements implicated in the maintenance of genome stability. Activation of CDK18 through cyclin binding further induces conformational changes that enhance substrate recognition and catalytic efficiency, thereby ensuring that the overall phosphorylation reaction is tightly linked to the specific signaling needs of differentiated cells (chowdhury2023cmgckinasesin pages 22-24).
3. Cofactor Requirements  
   In order for CDK18 to achieve catalytic activity, the kinase requires the presence of essential cofactors. As with other serine/threonine kinases, the activity of CDK18 is dependent on the presence of divalent metal ions, most notably magnesium (Mg²⁺), which plays a critical role in positioning the ATP molecule within the active site and stabilizing the transition state during phosphoryl group transfer (alonso2021caracterizacióndecdk1418 pages 114-118). In addition to Mg²⁺, the binding of specific regulatory partners, especially cyclins such as cyclin A2, is integral to its proper activation. Cyclin association not only helps to align the substrate within the catalytic cleft but also contributes to the conformational rearrangements required for full catalytic competence. Multiple lines of evidence support that no non-canonical metal ions are necessary for CDK18 activity, and the protein adheres to the conventional cofactor dependencies that are common among cyclin-dependent kinases (chowdhury2023cmgckinasesin pages 6-8).
4. Substrate Specificity  
   The substrate specificity of CDK18, while not completely defined, appears to conform generally to the properties of serine/threonine kinases that phosphorylate residues within a certain sequence context. Early experiments and sequence alignment analyses have suggested that CDK18 tends to phosphorylate serine and threonine residues often found within a motif that may involve adjacent proline, although its specificity is somewhat relaxed in comparison with canonical cell cycle CDKs that strictly prefer a [S/T]P motif (alonso2021caracterizacióndecdk1418 pages 114-118). Instead, CDK18’s relative flexibility in substrate recognition may allow it to target proteins involved in diverse signaling pathways, including those that regulate vesicle trafficking, cytoskeletal organization, and responses to DNA damage. This more permissive substrate specificity is thought to be partly attributable to its unique cyclin-binding characteristics; binding to cyclin A2, for instance, may induce conformational changes that expose catalytic and substrate-interaction surfaces, thereby facilitating phosphorylation of substrates that do not necessarily conform to a rigid consensus sequence (chowdhury2023cmgckinasesin pages 22-24). Additionally, emerging evidence suggests that modulation of substrate recognition by CDK18 might also be influenced by protein–protein interactions, where accessory or scaffolding proteins help direct the kinase toward specific substrates in the cellular context (pepino2021overviewofpctk3cdk18 pages 17-18).
5. Structure  
   The structural organization of CDK18 is characterized by a central catalytic kinase domain that adopts the typical bilobal fold common to eukaryotic protein kinases, with a smaller N-terminal lobe predominantly composed of β-sheets and a larger C-terminal lobe mainly consisting of α-helices (alonso2021caracterizacióndecdk1418 pages 29-32). Within this canonical kinase domain are several highly conserved motifs that are critical for the enzyme’s function. These include the VAIK motif, which is essential for proper ATP binding; the HRD motif, which plays a direct role in the catalytic mechanism; and the DFG motif, responsible for coordinating the Mg²⁺ ion that facilitates phosphoryl transfer (endicott2013structuralcharacterizationof pages 3-5). One of the defining structural features of CDK18 that sets it apart from classical CDKs is the presence of the PCTAIRE motif in lieu of the conventional PSTAIRE helix. This substitution is believed to affect both cyclin association and substrate presentation. In silico modeling and AlphaFold predictions have provided valuable insights in the absence of high-resolution crystallographic structures, confirming that CDK18 maintains the overall kinase fold yet incorporates N- and C-terminal extensions that may serve as additional regulatory docking platforms. These extensions are potentially involved in interactions with regulatory proteins such as 14-3-3, which can influence both the stability of CDK18 and its subcellular localization (karimbayli2024insightsintothe pages 13-14, pepino2021overviewofpctk3cdk18 pages 1-2). Although experimental structural data at atomic resolution are still pending, the conservation of key catalytic residues and the overall domain architecture strongly support the notion that CDK18 shares structural features with other cyclin-dependent kinases, while its unique motif substitutions underlie its specialized regulatory functions (alonso2021caracterizacióndecdk1418 pages 29-32, endicott2013structuralcharacterizationof pages 3-5).
6. Regulation  
   The regulation of CDK18 is multifaceted, involving both post-translational modifications and specific protein–protein interactions that collectively fine-tune its catalytic activity in a context-dependent manner. A primary regulatory mechanism is the phosphorylation of key serine residues by protein kinase A (PKA). Notably, phosphorylation at Ser12 has been identified as critical for CDK18 activation; phosphomimetic mutations at this residue have been shown to significantly enhance its kinase activity even in the absence of cyclin binding (matsuda2014pctairekinase3cyclindependent pages 1-2, pepino2021overviewofpctk3cdk18 pages 17-18). In addition to PKA-mediated phosphorylation, CDK18 requires association with activating cyclins, with cyclin A2 being the most significant partner reported thus far. Binding of cyclin A2 induces conformational rearrangements in CDK18 that are necessary for fully aligning the active site, thus facilitating efficient substrate phosphorylation (alonso2021caracterizacióndecdk1418 pages 32-35). Although interactions with cyclin E1 have been documented, these do not result in robust activation of the kinase, emphasizing the specificity of CDK18’s cyclin-mediated regulation (pepino2021overviewofpctk3cdk18 pages 17-18). Moreover, there is emerging evidence that binding to regulatory proteins such as 14-3-3 may occur in a phosphorylation-dependent manner, thereby affecting both the subcellular distribution and the stability of the CDK18 complex (karimbayli2024insightsintothe pages 17-18). Collectively, these regulatory mechanisms underscore how phosphorylation, via the action of upstream kinases like PKA, and the selective interaction with cyclins, notably cyclin A2, work in concert to ensure that CDK18 activity is precisely modulated in accordance with the signaling context of terminally differentiated cells (alonso2021caracterizacióndecdk1418 pages 32-35, matsuda2014pctairekinase3cyclindependent pages 1-2).
7. Function  
   CDK18 is predominantly expressed in terminally differentiated cells, and its tissue distribution highlights a specialized role in post-mitotic signaling rather than in promoting cell proliferation. Expression analyses indicate that CDK18 levels are elevated in tissues such as the brain, testis, kidney, and gastrointestinal tract, consistent with its involvement in non-proliferative functions (alonso2021caracterizacióndecdk1418 pages 16-26, pepino2021overviewofpctk3cdk18 pages 1-2). Functionally, CDK18 has been implicated in several key cellular processes. One of its notable roles is in maintaining genome integrity; experimental depletion of CDK18 leads to increased DNA damage and replication fork stalling, suggesting that it plays a part in the DNA damage response and in preserving genomic stability (alonso2021caracterizacióndecdk1418 pages 35-38). In addition, CDK18 appears to participate in the regulation of vesicle trafficking by modulating COPII-mediated transport from the endoplasmic reticulum to the Golgi apparatus—a critical process for ensuring proper protein secretion and membrane localization (alonso2021caracterizacióndecdk1418 pages 35-38). Beyond these functions, there is evidence that CDK18 influences actin cytoskeletal dynamics. Its activity can indirectly alter cell morphology and adhesion by affecting signaling pathways that control actin polymerization, processes particularly relevant in the context of differentiated cells that require specialized cytoskeletal remodeling for proper function (chowdhury2023cmgckinasesin pages 6-8). Moreover, aberrant expression and deregulation of CDK18 have been linked to oncogenic signaling pathways—for instance, through modulation of MYC and E2F target gene expression—although its precise role in tumorigenesis may vary depending on cellular context, with some studies suggesting potential tumor suppressive aspects in certain settings (alonso2021caracterizacióndecdk1418 pages 16-26, karimbayli2024insightsintothe pages 17-17). Collectively, these functional data present CDK18 as a versatile kinase that integrates signals from multiple pathways, contributing to genome maintenance, vesicle trafficking, and cytoskeletal regulation, which together underscore its importance in maintaining cellular homeostasis in terminally differentiated cells (chowdhury2023cmgckinasesin pages 6-8, pepino2021overviewofpctk3cdk18 pages 14-16).
8. Other Comments  
   Despite the growing recognition of CDK18’s biological importance, selective targeting of this kinase has proven challenging. The design of potent inhibitors is complicated by the atypical configuration of its cyclin-binding region, characterized by the PCTAIRE motif, which differentiates it structurally from classical CDKs and contributes to its relaxed substrate specificity (pepino2021overviewofpctk3cdk18 pages 1-2, alonso2021caracterizacióndecdk1418 pages 16-26). As a result, pan-CDK inhibitors have been unable to achieve the high degree of selectivity that would allow for the dissection of CDK18-specific functions in physiological and pathological conditions. This has spurred interest in alternative approaches, such as the development of peptide inhibitors designed to disrupt key protein–protein interactions or the application of proteolysis-targeting chimeras (PROTACs) to induce selective degradation of CDK18 (pepino2021overviewofpctk3cdk18 pages 1-2). Furthermore, ongoing research is focused on elucidating the regulatory interplay between CDK18 and its activating partners—particularly cyclin A2—and the post-translational modifications mediated by PKA, which may reveal novel structural features that can be exploited for drug design (matsuda2014pctairekinase3cyclindependent pages 1-2, pepino2021overviewofpctk3cdk18 pages 17-18). Disease associations have emerged from recent studies; for example, dysregulated CDK18 expression has been correlated with hepatocellular carcinoma as well as neurodegenerative disorders, notably Alzheimer’s disease, where misregulation of cell cycle–related signaling in post-mitotic neurons may contribute to disease progression (alonso2021caracterizacióndecdk1418 pages 35-38, karimbayli2024insightsintothe pages 17-18). Although these associations are largely correlative at this stage, they highlight the potential of CDK18 as a therapeutic target and emphasize the need for further mechanistic studies to fully understand its role in both normal physiology and disease pathology. Overall, CDK18 exemplifies an understudied yet promising kinase whose unique regulatory and functional properties necessitate additional in-depth investigation to harness its potential in precision medicine (pepino2021overviewofpctk3cdk18 pages 1-2, karimbayli2024insightsintothe pages 1-2).
9. References  
   alonso2021caracterizacióndecdk1418 pages 114-118, alonso2021caracterizacióndecdk1418 pages 16-26, alonso2021caracterizacióndecdk1418 pages 29-32, alonso2021caracterizacióndecdk1418 pages 32-35, alonso2021caracterizacióndecdk1418 pages 35-38, chowdhury2023cmgckinasesin pages 2-4, chowdhury2023cmgckinasesin pages 22-24, chowdhury2023cmgckinasesin pages 6-8, endicott2013structuralcharacterizationof pages 3-5, karimbayli2024insightsintothe pages 1-2, karimbayli2024insightsintothe pages 13-14, karimbayli2024insightsintothe pages 17-17, karimbayli2024insightsintothe pages 17-18, malumbres2014cyclindependentkinases pages 3-5, matsuda2014pctairekinase3cyclindependent pages 1-2, pepino2021overviewofpctk3cdk18 pages 1-2, pepino2021overviewofpctk3cdk18 pages 14-16, pepino2021overviewofpctk3cdk18 pages 17-18

References

1. (alonso2021caracterizacióndecdk1418 pages 114-118): D Martínez Alonso. Caracterización de cdk14-18 como dianas terapéuticas en carcinoma hepatocelular. Unknown journal, 2021.
2. (alonso2021caracterizacióndecdk1418 pages 16-26): D Martínez Alonso. Caracterización de cdk14-18 como dianas terapéuticas en carcinoma hepatocelular. Unknown journal, 2021.
3. (alonso2021caracterizacióndecdk1418 pages 29-32): D Martínez Alonso. Caracterización de cdk14-18 como dianas terapéuticas en carcinoma hepatocelular. Unknown journal, 2021.
4. (alonso2021caracterizacióndecdk1418 pages 32-35): D Martínez Alonso. Caracterización de cdk14-18 como dianas terapéuticas en carcinoma hepatocelular. Unknown journal, 2021.
5. (alonso2021caracterizacióndecdk1418 pages 35-38): D Martínez Alonso. Caracterización de cdk14-18 como dianas terapéuticas en carcinoma hepatocelular. Unknown journal, 2021.
6. (chowdhury2023cmgckinasesin pages 2-4): Iftekhar Chowdhury, Giovanna Dashi, and Salla Keskitalo. Cmgc kinases in health and cancer. Cancers, 15:3838, Jul 2023. URL: https://doi.org/10.3390/cancers15153838, doi:10.3390/cancers15153838. This article has 18 citations and is from a peer-reviewed journal.
7. (chowdhury2023cmgckinasesin pages 22-24): Iftekhar Chowdhury, Giovanna Dashi, and Salla Keskitalo. Cmgc kinases in health and cancer. Cancers, 15:3838, Jul 2023. URL: https://doi.org/10.3390/cancers15153838, doi:10.3390/cancers15153838. This article has 18 citations and is from a peer-reviewed journal.
8. (chowdhury2023cmgckinasesin pages 6-8): Iftekhar Chowdhury, Giovanna Dashi, and Salla Keskitalo. Cmgc kinases in health and cancer. Cancers, 15:3838, Jul 2023. URL: https://doi.org/10.3390/cancers15153838, doi:10.3390/cancers15153838. This article has 18 citations and is from a peer-reviewed journal.
9. (endicott2013structuralcharacterizationof pages 3-5): JA Endicott and MEM Noble. Structural characterization of the cyclin-dependent protein kinase family. Biochemical Society transactions, 41 4:1008-16, Aug 2013. URL: https://doi.org/10.1042/bst20130097, doi:10.1042/bst20130097. This article has 48 citations and is from a peer-reviewed journal.
10. (karimbayli2024insightsintothe pages 1-2): Javad Karimbayli, Ilenia Pellarin, Barbara Belletti, and Gustavo Baldassarre. Insights into the structural and functional activities of forgotten kinases: pctaires cdks. Molecular Cancer, Jun 2024. URL: https://doi.org/10.1186/s12943-024-02043-6, doi:10.1186/s12943-024-02043-6. This article has 4 citations and is from a highest quality peer-reviewed journal.
11. (karimbayli2024insightsintothe pages 13-14): Javad Karimbayli, Ilenia Pellarin, Barbara Belletti, and Gustavo Baldassarre. Insights into the structural and functional activities of forgotten kinases: pctaires cdks. Molecular Cancer, Jun 2024. URL: https://doi.org/10.1186/s12943-024-02043-6, doi:10.1186/s12943-024-02043-6. This article has 4 citations and is from a highest quality peer-reviewed journal.
12. (karimbayli2024insightsintothe pages 17-17): Javad Karimbayli, Ilenia Pellarin, Barbara Belletti, and Gustavo Baldassarre. Insights into the structural and functional activities of forgotten kinases: pctaires cdks. Molecular Cancer, Jun 2024. URL: https://doi.org/10.1186/s12943-024-02043-6, doi:10.1186/s12943-024-02043-6. This article has 4 citations and is from a highest quality peer-reviewed journal.
13. (karimbayli2024insightsintothe pages 17-18): Javad Karimbayli, Ilenia Pellarin, Barbara Belletti, and Gustavo Baldassarre. Insights into the structural and functional activities of forgotten kinases: pctaires cdks. Molecular Cancer, Jun 2024. URL: https://doi.org/10.1186/s12943-024-02043-6, doi:10.1186/s12943-024-02043-6. This article has 4 citations and is from a highest quality peer-reviewed journal.
14. (malumbres2014cyclindependentkinases pages 3-5): Marcos Malumbres. Cyclin-dependent kinases. Genome Biology, 15:122-122, Jun 2014. URL: https://doi.org/10.1186/gb4184, doi:10.1186/gb4184. This article has 1878 citations and is from a highest quality peer-reviewed journal.
15. (matsuda2014pctairekinase3cyclindependent pages 1-2): Shinya Matsuda, Kyohei Kominato, Shizuyo Koide-Yoshida, Kenji Miyamoto, Kinuka Isshiki, Akihiko Tsuji, and Keizo Yuasa. Pctaire kinase 3/cyclin-dependent kinase 18 is activated through association with cyclin a and/or phosphorylation by protein kinase a. Journal of Biological Chemistry, 289:18387-18400, Jun 2014. URL: https://doi.org/10.1074/jbc.m113.542936, doi:10.1074/jbc.m113.542936. This article has 36 citations and is from a domain leading peer-reviewed journal.
16. (pepino2021overviewofpctk3cdk18 pages 1-2): Rebeka de Oliveira Pepino, Fernanda Coelho, Tatiane Aparecida Buzanello Janku, Diandra Pinheiro Alencar, Walter Figueira de Azevedo, and Fernanda Canduri. Overview of pctk3/cdk18: a cyclin-dependent kinase involved in specific functions in post-mitotic cells. Current Medicinal Chemistry, 28:6846-6865, Oct 2021. URL: https://doi.org/10.2174/0929867328666210329122147, doi:10.2174/0929867328666210329122147. This article has 9 citations and is from a peer-reviewed journal.